R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K. · 2015
Read R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. by Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5068814.txt.
Introduction
C. Yang and seven co-authors compare the two mirror forms of ketamine in Translational Psychiatry in 2015. Ketamine lifts depression within hours and holds for days, a rare profile, but its side effects and abuse risk limit clinic use. The drug mixes two mirror-image forms, R and S. The team gave each form to mice in two depression models and probed benefit and side effects.
R-ketamine beat S-ketamine on strength and staying power in the social defeat and learned helplessness models. It better restored lost dendritic spines, growth signaling, and new synapse building in the prefrontal cortex and two hippocampus regions. On side-effect tests the split was clean: S-ketamine drove restless movement, sensing glitches, reward seeking, and loss of a brain cell class. R-ketamine did none of these. The authors present R-ketamine as the safer, longer-acting half in mice.
Catalog record
| CREATOR | Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects By C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto Published in: Translational Psychiatry DOI: 10.1038/tp.2015.136 ABSTRACT Abstract Although the efficacy of racemate ketamine, a rapid onset and sustained antidepressant, for patients with treatment-resistant depression was a serendipitous finding, clinical use of ketamine is limited, due to psychotomimetic side effects and abuse liability. Behavioral and side-effect evaluation tests were applied to compare the two stereoisomers of ketamine. To elucidate their potential therapeutic mechanisms, we examined the effects of these stereoisomers on brain-derived neurotrophic factor (BDNF)–TrkB signaling, and synaptogenesis in selected brain regions. In the social defeat stress and learned helplessness models of depression, R-ketamine showed a greater potency and longer-lasting antidepressant effect than S-ketamine (esketamine). Furthermore, R-ketamine induced a more potent beneficial effect on decreased dendritic spine density, BDNF–TrkB signaling and synaptogenesis in the prefrontal cortex (PFC), CA3 and dentate gyrus (DG) of the hippocampus from depressed mice compared with S-ketamine. However, neither stereoisomer affected these alterations in the nucleus accumbens of depressed mice. In behavioral tests for side effects, S-ketamine, but not R-ketamine, precipitated behavioral abnormalities, such as hyperlocomotion, prepulse inhibition deficits and rewarding effects. In addition, a single dose of S-ketamine, but not R-ketamine, caused a loss of parvalbumin (PV)-positive cells in the prelimbic region of the medial PFC and DG. These findings suggest that, unlike S-ketamine, R-ketamine can elicit a sustained antidepressant effect, mediated by increased BDNF–TrkB signaling and synaptogenesis in the PFC, DG and CA3. R-ketamine appears to be a potent, long-lasting and safe antidepressant, relative to S-ketamine, as R-ketamine appears to be free of psychotomimetic side effects and abuse liability. INTRODUCTION As well as being the most prevalent, major depressive disorder is also among the most severe and debilitating of the psychiatric illnesses. The World Health Organization estimates that more than 350 million individuals of all ages suffer from depression.1 Almost one million lives are lost annually due to suicide, which translates to 3000 deaths daily.1 Although antidepressants are generally effective in the treatment of major depressive disorder, it can still take weeks before patients feel the full therapeutic benefit. In addition, approximately two-thirds of these patients fail to respond to pharmacotherapy and for those that do, there is a high rate of relapse.2 This highlights the unmet need for therapeutic agents with a rapid onset of action, particularly for patients who do not respond to current antidepressants, many of whom are at an increased risk of suicide.3 In this setting, the glutamatergic system represents a promising therapeutic target for major depressive disorder.4, 5, 6, 7, 8, 9 Over the past decade, the fast-acting antidepressant effects of the N-methyl-d-aspartate (NMDA) receptor antagonist, ketamine, represent one of the most attractive discoveries in the field of psychiatry.3, 10, 11 A sub-anesthetic dose (0.5 mg kg−1) of ketamine confers a rapid antidepressant benefit in depressed patients,12 including treatment-resistant depression and treatment-resistant bipolar depression.13, 14, 15, 16 Ketamine elicits its rapid antidepressant effect within a couple of hours, and this effect can be sustained for up to 2 weeks in some patients. Crucially, ketamine is reported to exert rapid effects against suicidal ideation.17, 18, 19 Recent meta-analyses support the rapid therapeutic action of ketamine in treatment-resistant patients.20, 21, 22 Ketamine (or RS-ketamine) is a racemic mixture containing equal parts of R-ketamine and S-ketamine. S-ketamine has an approximately fourfold greater affinity for the NMDA receptor than the R-ketamine.10 Furthermore, S-ketamine shows an approximately three- to fourfold greater anesthetic potency and greater undesirable psychotomimetic side effects, compared with R-ketamine.10, 23 These findings lend weight to the general acceptance that the anesthetic and psychotomimetic actions of ketamine are mediated primarily via the blockade of NMDA receptors.10, 23, 24 In the depression model after neonatal dexamethasone exposure, we reported that R-ketamine showed greater potency and longer-lasting antidepressant effects than S-ketamine,25 indicating that R-ketamine may be a potent and safe antidepressant relative to S-ketamine.26, 27 The purpose of this study was to compare the two stereoisomers of ketamine in the social defeat stress and learned helplessness models of depression. In addition, we examined the effects of these stereoisomers on brain-derived neurotrophic factor (BDNF)–TrkB signaling, and synaptogenesis in selected brain regions, as these may be implicated in ketamine's antidepressant effects.9, 28, 29, 30, 31, 32, 33 Finally, we examined the action of these stereoisomers on a profile of side effects, including psychotomimetic effects and drug abuse potential. MATERIALS AND METHODS Animals Male adult C57BL/6 mice, aged 8 weeks (body weight 20–25 g, Japan SLC, Hamamatsu, Japan) and male adult CD1 (ICR) mice, aged 13–15 weeks (body weight >40 g, Japan SLC) were used for the social defeat stress model. Male Sprague Dawley rats (200–230 g, 7 week olds, Charles River Japan, Tokyo, Japan) were used for the learned helplessness (LH) model. Animals were housed under controlled temperatures and 12-h light/dark cycles (lights on between 0700 and 1900 hours), with ad libitum food (CE-2; CLEA Japan, Tokyo, Japan) and water. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Chiba University Institutional Animal Care and Use Committee. Materials R-ketamine hydrochloride and S-ketamine hydrochloride were prepared by recrystallization of RS-ketamine (Ketalar, ketamine hydrochloride, Daiichi Sankyo Pharmaceutical, Tokyo, Japan) and d-(−)-tartaric acid (or l- (+)-tartaric acid), as described previously.34 The purity of these stereoisomers was determined by a high-performance liquid chromatography (CHIRALPAK IA, column size: 250 × 4.6 mm, mobile phase: n-hexane/dichloromethane/diethylamine (75/25/0.1), Daicel, Tokyo, Japan). NBQX, 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (catalog number: 0373, Tocris Bioscience, Bristol, UK, 10 mg kg−1) was dissolved in saline. ANA-12, N2-(2-{[(2-oxoazepan-3-yl) amino]carbonyl}phenyl)benzo[b]thiophene-2-carboxamide (catalog number: BTB06525SC, Maybridge, Trevillett Tintagel, Cornwall, UK, 0.5 mg kg−1) was prepared in vehicle of 1% dimethylsulfoxide in phosphate-buffered saline. The dose of ketamine, NBQX and ANA-12 was selected as reported previously.34, 35, 36, 37, 38, 39, 40 Other reagents were purchased commercially. Social defeat stress model The procedure of social defeat stress was performed as previously reported.41, 42 Every day the C57BL/6 mice were exposed to a different CD1 aggressor mouse for 10 min, total for 10 days. When the social defeat session ended, the resident CD1 mouse and the intruder mouse were housed in one half of the cage separated by a perforated Plexiglas divider to allow visual, olfactory and auditory contact for the remainder of the 24- h period. At 24 h after the last session, all mice were housed individually. On day 11, a social avoidance test was performed to identify subgroups of mice that were susceptible and unsusceptible to social defeat stress. This was accomplished by placing mice in an interaction test box (42 × 42 cm) with an empty wire-mesh cage (10 × 4.5 cm) located at one end. The movement of the mice was tracked for 2.5 min, followed by 2.5 min in the presence of an unfamiliar aggressor confined in the wire-mesh cage. The duration of the subject's presence in the 'interaction zone' (defined as the 8-cm-wide area surrounding the wire-mesh cage) was recorded by a stopwatch. The interaction ratio was calculated as the time spent in an interaction zone with an